Stem cell based cancer gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Stem Cell Biology

Background:

• Prodrug cancer gene therapy aims to activate therapeutic agents within tumor masses to minimize systemic toxicity.
• Suicide gene therapy using genetically engineered mesenchymal stem cells offers a safety advantage by eliminating both tumor cells and resistant therapeutic stem cells post-prodrug administration.

Purpose of the Study:

• To explain the principles of stem cell-targeted prodrug cancer gene therapy.
• To review key components including prodrug selection, stem cell properties (mesenchymal and neural), and tumor homing mechanisms.
• To discuss therapeutic achievements and future directions in stem cell-mediated antitumor strategies.

Main Methods:

• Review of existing literature on stem cell-targeted prodrug cancer gene therapy.
• Focus on mesenchymal stem cells (bone marrow and adipose-derived) and neural stem cells.
• Analysis of specific prodrug systems (cytosine deaminase/5-fluorocytosine and HSVtk/ganciclovir) and their therapeutic outcomes.

Main Results:

• Stem cell-targeted therapy enables localized prodrug activation, enhancing efficacy and reducing side effects.
• Mesenchymal and neural stem cells demonstrate tumor-homing capabilities suitable for targeted delivery.
• Successful therapeutic outcomes have been reported for specific prodrug systems, with potential for broader applications.

Conclusions:

• Stem cell-targeted prodrug gene therapy presents a promising strategy for localized cancer treatment with improved safety profiles.
• The delivery of various therapeutic payloads, including cytokines, apoptosis-inducing genes, and nanoparticles, via stem cells offers versatile antitumor approaches.
• Combining conventional, targeted, and stem cell-directed gene therapies holds significant potential for advancing cancer treatment modalities.